NCT05383872 is a NA clinical trial of Focused Ultrasound (Exablate Model 4000) in Glioblastoma, sponsored by InSightec.

Who is sponsoring NCT05383872?

NCT05383872 is sponsored by InSightec.

What drugs are being tested in NCT05383872?

Interventions in NCT05383872: Focused Ultrasound (Exablate Model 4000).

What condition does NCT05383872 study?

NCT05383872 studies Glioblastoma, Glioma, Liquid Biopsy.

Is NCT05383872 still recruiting?

NCT05383872 is currently completed. Last updated 28 July 2025.

Last reviewed 2025-07-28 · How we verify

NCT05383872

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects With GlioBlastoma Brain Tumors

Completed NA Last updated 28 July 2025

What this trial tests

NA trial testing Focused Ultrasound (Exablate Model 4000) in Glioblastoma in 71 participants. Completed in 5 March 2025.

Timeline

8 August 2022

Primary endpoint
21 February 2025

5 March 2025

Quick facts

Lead sponsor	InSightec
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	71
Start date	8 August 2022
Primary completion	21 February 2025
Estimated completion	5 March 2025
Sites	17 locations across Canada, United States

Drugs / interventions tested

Focused Ultrasound (Exablate Model 4000)

Conditions studied

Glioblastoma — all drugs for Glioblastoma →
Glioma — all drugs for Glioma →
Liquid Biopsy — all drugs for Liquid Biopsy →

Sponsor

InSightec — full company profile →

Who can join

Adults 18 to 80, any sex, with Glioblastoma or Glioma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type 2.0/2.1 for liquid biopsy in subjects with suspected Glioblastoma brain tumors

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Circulating Liquid Biopsy Biomarkers in Glioblastoma: Advances and Challenges.
Seyhan AA. · · 2024 · cited 44× · PMID 39063215 · DOI 10.3390/ijms25147974
Focused ultrasound-mediated enhancement of blood-brain barrier permeability for brain tumor treatment: a systematic review of clinical trials.
Zhu H, Allwin C, Bassous MG, Pouliopoulos AN. · · 2024 · cited 34× · PMID 39207625 · DOI 10.1007/s11060-024-04795-z
Liquid biopsy and glioblastoma.
Eibl RH, Schneemann M. · · 2023 · cited 24× · PMID 36937320 · DOI 10.37349/etat.2023.00121
Device-assisted strategies for drug delivery across the blood-brain barrier to treat glioblastoma.
Mokarram N, Case A, Hossainy NN, Lyon JG, et al · · 2025 · cited 17× · PMID 39790893 · DOI 10.1038/s43246-024-00721-y
Microbubble-Enhanced Focused Ultrasound for Infiltrating Gliomas.
Seas AA, Malla AP, Sharifai N, Winkles JA, et al · · 2024 · cited 13× · PMID 38927437 · DOI 10.3390/biomedicines12061230
Liquid biopsy: creating opportunities in brain space.
Trivedi R, Bhat KP. · · 2023 · cited 13× · PMID 37752289 · DOI 10.1038/s41416-023-02446-0
Immune checkpoint inhibitors for glioblastoma: emerging science, clinical advances, and future directions.
Badani A, Ozair A, Khasraw M, Woodworth GF, et al · · 2025 · cited 12× · PMID 39570554 · DOI 10.1007/s11060-024-04881-2
Updates for newly diagnosed and recurrent glioblastoma: a review of recent clinical trials.
Fukushima CM, de Groot J. · · 2024 · cited 11× · PMID 39258745 · DOI 10.1097/wco.0000000000001320

Verify or expand the search:

Other recruiting trials for Glioblastoma

Currently open trials in the same condition.

NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
NCT05653635 — Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study · Phase 2 · recruiting
NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
NCT07448480 — Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas · active not recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other InSightec trials

Trials by the same sponsor.

NCT04667715 — Safety and Effectiveness of Blood-Brain Barrier Disruption (BBBD) in Subjects With Suspected Infiltrating Glioma · NA · withdrawn
NCT05539196 — A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advance · recruiting
NCT05089786 — Echo-Focusing in Patients With Treatment-Resistant Neurologic and Psychiatric Indications (EF001) · NA · unknown
NCT05565443 — MR-guided Focused Ultrasound Plus GCase · NA · recruiting
NCT05317858 — Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05383872 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by InSightec
Last refreshed: 28 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05383872.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing